Genelux (GNLX) Stock Price, News & Analysis

Company Overview

Genelux Corporation is a clinical-stage biotechnology company focused on developing novel cancer treatments based on oncolytic virus immunotherapies. The company’s platform is designed to use genetically modified viruses to selectively infect and destroy tumor cells while stimulating the patient’s immune system to recognize and attack cancer.

Genelux’s lead product candidate is Olvi-Vec (olvimulogene nanivacirepvec), a proprietary modified vaccinia virus being studied in combination with other therapies for advanced solid tumors. The company has focused development efforts on ovarian cancer and is also evaluating Olvi-Vec in additional cancer types, including colorectal and lung cancers.

Genelux is headquartered in San Diego, California, and conducts its research and clinical development activities through collaborations and clinical studies in the United States and other regions. The company’s work is centered on advancing its oncolytic virus platform and developing potential treatments for patients with difficult-to-treat cancers.

Key Stats

• Today's Range: $2.47 to $2.57
• 50-Day Range: $2.34 to $2.98
• 52-Week Range: $2.29 to $8.53
• Volume: 154,650 shs
• Average Volume: 237,100 shs
• Market Capitalization: $115.81 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $18.00
• Consensus Rating: Moderate Buy

Genelux Stock Analysis - MarketRank™

Genelux scored higher than 48% of companies evaluated by MarketBeat, and ranked 528th out of 881 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.0 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Genelux has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 1 strong buy rating, 3 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

Genelux has a consensus price target of $18.00, representing about 603.1% upside from its current price of $2.56.

Amount of Analyst Coverage

Genelux has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Genelux are expected to grow in the coming year, from ($0.81) to ($0.68) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Genelux is -2.98, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Genelux is -2.98, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Genelux has a P/B Ratio of 8.53. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

10.42% of the float of Genelux has been sold short.

Short Interest Ratio / Days to Cover

Genelux has a short interest ratio ("days to cover") of 20.43, which indicates bearish sentiment.

Change versus previous month

Short interest in Genelux has recently increased by 6.49%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Genelux does not currently pay a dividend.

Dividend Growth

Genelux does not have a long track record of dividend growth.

News and Social Media

• Score: 2.8 / 5
• News Sentiment: 0.51

News Sentiment

Genelux has a news sentiment score of 0.51. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.39 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Genelux this week, compared to 3 articles on an average week.

Search Interest

3 people have searched for GNLX on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.

Company Ownership

• Score: 1.4 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Genelux insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $129,482.00 in company stock.

Percentage Held by Insiders

7.50% of the stock of Genelux is held by insiders.

Percentage Held by Institutions

37.33% of the stock of Genelux is held by institutions.

Company Calendar

• Last Earnings: 8/13/2026
• Today: 10/09/2026
• Next Earnings (Estimated): 11/04/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:GNLX
• CIK: 1231457
• Web: www.genelux.com
• Phone: 805-267-9889
• Fax: N/A
• Employees: 26
• Year Founded: 2001

Price Target and Rating

• Average Price Target for Genelux: $18.00
• High Price Target: $20.00
• Low Price Target: $16.00
• Potential Upside/Downside: +603.1%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.80
• Research Coverage: 5 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.86)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$32.15 million
• Net Margins: N/A
• Pretax Margin: -444,950.00%
• Return on Equity: -205.85%
• Return on Assets: -138.79%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.39
• Quick Ratio: 2.39

Sales & Book Value

• Annual Sales: $10 thousand
• Price / Sales: 11,581.44
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.30 per share
• Price / Book: 8.53

Miscellaneous

• Outstanding Shares: 45,240,000
• Free Float: 41,852,000
• Market Cap: $115.81 million
• Optionable: Not Optionable
• Beta: 0.59